Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial

Ignacio Párraga-Martínez, Joseba Rabanales-Sotos, Fernando Lago-Deibe, Juan M Téllez-Lapeira, Francisco Escobar-Rabadán, Alejandro Villena-Ferrer, Mariano Blasco-Valle, José M Ferreras-Amez, Susana Morena-Rayo, José M del Campo-del Campo, Maria Candelaria Ayuso-Raya, José J Pérez-Pascual, Ignacio Párraga-Martínez, Joseba Rabanales-Sotos, Fernando Lago-Deibe, Juan M Téllez-Lapeira, Francisco Escobar-Rabadán, Alejandro Villena-Ferrer, Mariano Blasco-Valle, José M Ferreras-Amez, Susana Morena-Rayo, José M del Campo-del Campo, Maria Candelaria Ayuso-Raya, José J Pérez-Pascual

Abstract

Background: In subjects with hypercholesterolaemia, cholesterol values remain above guideline levels. One of the limiting factors to the achievement of goals in such patients is therapeutic non-adherence. The aim of this study is to assess the effectiveness of an intervention designed to improve control of hypercholesterolaemic patients, consisting of a combined strategy that would include the delivery of printed information, treatment-compliance check cards and the dispatch of text messages as complementary measures in support of the intervention at the general practitioner's practice.

Methods/design: A randomised, parallel-group clinical trial will be conducted at the family medicine outpatient facilities of eight health centres in three of Spain's Autonomous Regions (Comunidades Autónomas), covering a total of 358 subjects aged 18 years or over with diagnosis of hypercholesterolaemia. Patients in the intervention group will be supplied with printed material with information on the disease and its management, mobile-telephone text messages with guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance, and self-report cards to check compliance with recommendations. Both groups -intervention and control- will receive routine recommendations from their physicians in accordance with current European clinical practice guidelines for hypercholesterolaemia and cardiovascular risk management. As regards the measurements to be made, the main variable is the proportion of subjects who attain the low density lipoprotein cholesterol levels set as a target across a follow-up period of 24 months. The secondary variables are as follows: adherence to recommendations on lifestyle and adherence to drug treatment; variation in lipid profiles and cardiovascular risk levels; appearance of cardiovascular events; physical activity; food consumption; smoking habit; anthropometric measures; blood pressure; health problems; use of hypolipidaemic agents; socio-demographic data; beliefs and expectations about preventive recommendations; and degree of satisfaction with the combined strategy.

Discussion: Should this intervention prove effective, a recommendation could be issued on the application of this combined strategy to subjects with hypercholesterolaemia. It is a simple, relatively inexpensive intervention.

Trial registration: ClinicalTrials.gov: NCT02314663.

References

    1. Medrano MJ, Cerrato E, Boix R, Delgado-Rodriguez M. Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med Clin (Bar) 2005;124:606–12. doi: 10.1157/13074389.
    1. Gabriel R, Alonso M, Segura A, Tormo MJ, Artigao LM, Banegas JR, et al. Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE Study. Rev Esp Cardiol. 2008;61:1030–40. doi: 10.1157/13126043.
    1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil. 2007;28:2375–414.
    1. Marrugat J, Solanas P, D’Agostino R, Sullivan I, Ordovas J, Cordón F, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56:253–61. doi: 10.1016/S0300-8932(03)76861-4.
    1. Lobos JM, Royo-bordonada M, Brotons C, Álvarez-Sala L, Armario P, Maiques A, et al. Guía Europea de prevención cardiovascular en la práctica clínica: adaptación española del CEIPC 2008. Rev Esp Salud Pública. 2008;82:581–616. doi: 10.1590/S1135-57272008000600002.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Circulation. 2002;106:3143–421.
    1. Reiner Z, Catapano A, De Backer C, Graham I, Taskinen M, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J. 2011;32:1769–818. doi: 10.1093/eurheartj/ehr158.
    1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929–40. doi: 10.1016/S0140-6736(09)60330-5.
    1. Vegazo O, Banegas JR, Civeira F, Serrano Aisa P, Jiménez FJ, Luengo E, et al. Prevalence of dyslipidemia in outpatients of the Spanish health service: the HISPALIPID Study. Med Clin (Barc) 2006;127:331–4. doi: 10.1157/13092314.
    1. Alvarez-Sala LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al. PREVENCAT study: control of cardiovascular risk in primary care. Med Clin (Barc) 2005;124:406–10. doi: 10.1157/13072841.
    1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–37. doi: 10.1097/HJR.0b013e3283294b1d.
    1. Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34. doi: 10.1161/CIRCULATIONAHA.108.838466.
    1. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;371:1999–2012. doi: 10.1016/S0140-6736(08)60868-5.
    1. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med. 2010;51:494–6. doi: 10.1016/j.ypmed.2010.09.015.
    1. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61. doi: 10.1001/jama.288.4.455.
    1. Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, et al. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther. 2011;33(9):1180–9. doi: 10.1016/j.clinthera.2011.07.007.
    1. World Health Organization . Adherence to long term therapies: evidence for action. 2003.
    1. Bueno M, Barrionuevo MD, Fikri N, García-Jiménez E. Causes of non-compliance of patients who attend a community pharmacy in Granada. Aten Primaria. 2008;40:101–6.
    1. Gil-Guillén V, Merino-Sánchez J, Sánchez-Ruiz T, Amorós-Barber T, Aznar-Vicente J, Abellán-Alemán J, et al. Valoración del riesgo cardiovascular en la fase transversal del estudio Mediterránea. Rev Clin Esp. 2009;209:211–20. doi: 10.1016/S0014-2565(09)71237-8.
    1. Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143–52. doi: 10.1093/eurheartj/ehr080.
    1. Márquez E, Casado JJ, Corchado Y, Chaves R, Grancío A, Losada C, et al. Eficacia de una intervención para mejorar el cumplimiento terapéutico en las dislipemias. Aten Primaria. 2004;33(8):443–50. doi: 10.1016/S0212-6567(04)79430-5.
    1. Márquez E, Gil V, Casado JJ, Martel N, de la Figuera M, Martin JL, et al. Análisis de estudios publicados sobre el incumplimiento terapéutico en el tratamiento de la hipertensión arterial en España entre los años 1984–2005. Aten Primaria. 2006;38:325–32. doi: 10.1157/13093369.
    1. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489–95.
    1. Palop V, Martínez I. Adherencia al tratamiento en el paciente anciano. Inf Ter Sist Nac Salud. 2004;28:113–20.
    1. McDonald P, Garg AX, Haynes RB. Intervention to enhance patient adherente to medication prescriptions (SR) JAMA. 2002;288:2868–79. doi: 10.1001/jama.288.22.2868.
    1. Gibbs S, Waters WE, George CF. The beneficits of prescription information leaflets. Br J Clin Pharmacol. 1989;27:723–73. doi: 10.1111/j.1365-2125.1989.tb03434.x.
    1. Baker D, Roberts DE, Newcombe RG, Fox KA. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol. 1991;31:525–31. doi: 10.1111/j.1365-2125.1991.tb05574.x.
    1. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacoterapy. 1999;19:860–9. doi: 10.1592/phco.19.10.860.31565.
    1. Erickson SR, Slaughter R, Halapy H. Pharmacists’ ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997;17:140–7.
    1. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipidlowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20:410–6. doi: 10.1592/phco.20.5.410.35048.
    1. Bodiya A, Vorias D, Dickson HA. Does telephone contac with a physicians’s office staff improve mammogram screening rates? Fam Med. 1999;31:324–6.
    1. Batalla C. Comentario: una herramienta más para mejorar el cumplimiento terapéutico. Aten Primaria. 2009;41:191–2. doi: 10.1016/j.aprim.2008.12.005.
    1. Haynes RB, McKibbon KA, Kanani R, Brouwers C, Oliver T. Cochrane collaboration: cochrane library. Oxford: Update Software; 1998. Interventions to assist patients to follow prescriptions for medications.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj